arGEN-X Presents ARGX-111 at Targeted Anticancer Therapies

March 02, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, presented clinical potential of ARGX-111 in hematological malignancies and suppression of metastasis at Targeted Anticancer Therapies (TAT), Paris, France.

arGEN-X won the Best Poster award.